ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 272 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $243,953 | -28.2% | 9,079 | -4.7% | 0.01% | -22.2% |
Q2 2023 | $339,590 | +35.5% | 9,523 | -3.5% | 0.01% | +28.6% |
Q1 2023 | $250,546 | -35.9% | 9,864 | +2.3% | 0.01% | -36.4% |
Q4 2022 | $390,958 | +22.6% | 9,639 | 0.0% | 0.01% | +10.0% |
Q3 2022 | $319,000 | -5.9% | 9,639 | 0.0% | 0.01% | +25.0% |
Q2 2022 | $339,000 | -22.1% | 9,639 | +1.9% | 0.01% | 0.0% |
Q1 2022 | $435,000 | -29.8% | 9,462 | +1.2% | 0.01% | -27.3% |
Q4 2021 | $620,000 | +6.2% | 9,350 | 0.0% | 0.01% | -8.3% |
Q3 2021 | $584,000 | -26.3% | 9,350 | -2.2% | 0.01% | -25.0% |
Q2 2021 | $792,000 | +22.6% | 9,565 | -1.8% | 0.02% | +14.3% |
Q1 2021 | $646,000 | -13.5% | 9,740 | 0.0% | 0.01% | -17.6% |
Q4 2020 | $747,000 | +74.5% | 9,740 | -2.0% | 0.02% | +70.0% |
Q3 2020 | $428,000 | -3.6% | 9,934 | -3.3% | 0.01% | -9.1% |
Q2 2020 | $444,000 | +50.0% | 10,277 | 0.0% | 0.01% | +37.5% |
Q1 2020 | $296,000 | -54.6% | 10,277 | 0.0% | 0.01% | -42.9% |
Q4 2019 | $652,000 | – | 10,277 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Western Financial Corp/CA | 820,320 | $33,272,179 | 21.56% |
Aquilo Capital Management, LLC | 1,103,515 | $44,758,568 | 16.81% |
M28 Capital Management LP | 143,900 | $5,836,584 | 5.56% |
WEALTH EFFECTS LLC | 155,620 | $6,311,951 | 3.60% |
Evolutionary Tree Capital Management, LLC | 92,095 | $3,735,373 | 3.59% |
Privium Fund Management B.V. | 221,015 | $8,867,122 | 3.36% |
JOHNSON & JOHNSON | 247,598 | $10,043 | 2.92% |
COMMODORE CAPITAL LP | 462,111 | $18,743 | 2.82% |
Avidity Partners Management LP | 1,375,000 | $55,770,000 | 1.21% |
Capital Impact Advisors, LLC | 26,853 | $1,089,158 | 1.06% |